Main Text {#sec1}
=========

Asthma is a chronic disease, currently affecting more than 300 million people worldwide and anticipated to increase to 400 million by 2025. Approximately 250,000 asthma-related deaths are reported yearly, many of which are avoidable ([@bib35]). The pathogenesis of asthma is still not well understood, but the disease has been linked to several genetic, environmental, infectious, and nutritional factors. In the early 1900s, asthma was described as a single disease, but our understanding of its complexity has evolved to the point where precision medicine approaches, including microbiome analysis, are starting to emerge for its diagnosis and treatment ([@bib47], [@bib154]).

Given the huge number of different microorganisms that colonize the human body, their intimate contact with human cells and their multiple influences on the host, the human microbiome is no longer considered inert. Microbial communities of the respiratory and gastrointestinal tracts are essential in maintaining human health. The healthy adult microbiota, which includes bacteria, viruses, fungi, and even archaea, is diverse, stable, resistant, and resilient, meaning it is rich in many different species and can normally return to the pre-perturbation state ([@bib95]).

Microbial dysbiosis within the lungs and gut in asthma can be caused by many factors related to lifestyle and environmental exposures. Imbalance between the symbiotic and pathological bacterial strains in the gut and lung may lead to altered immune development and inappropriate inflammatory responses, but it is still unclear whether the imbalance is the cause or effect of disease. This review will address the question and focus on the role of the lung and gut microbiota in the development and maintenance of respiratory health and its disturbances in different subtypes of asthma.

Asthma Is Not a Single Disease {#sec1.1}
------------------------------

Asthma is characterized by a large spectrum of clinically observed phenotypes and an even larger range of underlying molecular and immunological mechanisms, called endotypes ([@bib171], [@bib149], [@bib22]). Currently, the best understanding of these complex endotypes as mechanistic pathogenetic processes lays in their dualistic division as type 2 or non-type 2 asthma ([@bib3]) ([Figure 1](#fig1){ref-type="fig"} A). However, often endotypes can co-exist and/or include other mixed processes, which cannot be easily categorized ([@bib91], [@bib3], [@bib40]). Less well-defined forms of asthma, situated between clinical phenotypes and molecular endotypes, include inflammatory phenotypes of eosinophilic, neutrophilic, mixed, and paucigranulocytic asthma ([@bib168], [@bib153]).Figure 1Schematic Representation of Asthma Phenotypes and Endotypes with Differences in Microbiota between Endotypes and Simplified Cellular Mechanisms Involved in Asthma and Its Correlation with Microbiota(A) Schematic representation of asthma phenotypes and endotypes with differences in microbiota between endotypes. Endotypes classify asthma based on pathophysiological mechanisms, whereas phenotype refers to the clinical and morphological description of disease. The two best-described asthma endotypes are the type 2 endotype, which includes mostly Th2 cell responses, and the non-type 2 endotype. However, endotypes can co-exist and/or include other mixed processes. Type 2 asthma is usually observed in the clinic as early-onset allergic asthma, late-onset eosinophilic asthma, or exercise-induced asthma. Non-type 2 asthma mechanisms are observed usually in neutrophilic, obesity-related, and paucigranulocytic phenotypes.(B) Simplified cellular mechanisms involved in asthma and its correlation with microbiota. Th2-cell-driven inflammation engages Th 2 cells, type 2 innate lymphoid cells, T follicular helper cells, type 2 B cells, eosinophils, and mast cells and results in increased amounts of IL-4, IL-5, IL-9, IL-13, prostaglandin D2, and CCR8 in sputum, BAL, serum, and bronchial biopsies. Non-type 2 asthma is characterized by infiltration of Th1 and Th17 cells, neutrophils, and the presence of type I interferons, NLRP3 inflammasome, and IL-1β and IL-17 cytokines.

Type 2 asthma is usually observed in the clinic as early-onset allergic asthma, late-onset eosinophilic asthma, or exercise-induced asthma ([@bib56]). These patients are usually allergic to common aeroallergens, have high blood eosinophilia, increased periostin, and high exhaled nitric oxide. They tend to respond well to treatment with glucocorticosteroids or novel biologicals, such as anti-immunoglobulin E (IgE), anti-interleukin-5 (IL-5), or anti-IL-4 and anti-IL-13 approaches ([@bib28], [@bib39]). However, within high eosinophilic asthma, there are also those whose eosinophilia is resistant to steroid treatment and others with persistent severe asthma, who demonstrate a rapid decline in lung function, enhanced airway remodeling, and frequent exacerbations ([@bib37], [@bib117]). Mechanistically, type 2 inflammation engages T helper (Th) type 2 cells, type 2 innate lymphoid cells, T follicular helper cells, type 2 B cells, eosinophils, mast cells, and "signature" type 2 mediators including the cytokines IL-4, IL-5, and IL-13 as well as prostaglandin D2 ([@bib126]) ([Figure 1](#fig1){ref-type="fig"}B).

Non-type 2 asthma, observed more often in obesity-related asthma, neutrophilic asthma, and paucigranulocytic asthma ([@bib91], [@bib40], [@bib126]), is usually connected with poor responsiveness to steroids and more severe phenotypes, even in childhood ([@bib124]). Non-type 2 inflammation is characterized by infiltration of Th1 and Th17 cells and neutrophils, the presence of type I interferons, NLRP3 inflammasome activation, and an IL-1β and IL-17 signature ([@bib130], [@bib87], [@bib153]). The effect of microbiota dysbiosis on asthma heterogeneity seems intuitive, but, until recently ([@bib154], [@bib22]), lung and gut microbiome composition have not been addressed in studies on clinical or inflammatory phenotypes and endotypes of asthma.

Healthy Lungs Are Not Sterile {#sec1.2}
-----------------------------

Microbes had already inhabited every environmental niche on earth, including the most extreme, prior to humans. Therefore, it is not surprising that all surfaces of the human body, including the upper respiratory tract (URT) and lower respiratory tract (LRT), are populated with microbial communities. Yet, even upon initiation of the Human Microbiome Project in 2007 ([@bib160]), lungs were not sampled, partially due to the existing dogma at the time that lungs are sterile. This dogma significantly delayed the initiation of studies on the lung microbiota relative to the gut microbiota ([@bib50], [@bib110]) and likely persisted for several reasons: (1) healthy lungs were often not examined by invasive bronchoscopy techniques due to ethical concerns; (2) culture-based techniques were limited to known pathogens; and (3) bronchoscopy techniques were suspected to carry contamination from the oropharynx or nasal cavity. However, a pioneer publication using culture-independent 16S rRNA sequencing revealed differences in the microbial communities found in various locations of the healthy respiratory tract relative to those found in the respiratory tract of patients with asthma and chronic obstructive pulmonary disease (COPD) ([@bib75]). Numerous other studies confirming this observation have followed, elucidating the special role of the airway microbiota in health ([@bib103]) and disease ([@bib178]).

The respiratory system in humans consists of an URT, starting with the nasal cavity followed by the nasopharynx, oropharynx, and larynx above the vocal cords; and LRT, continuing in the larynx below the vocal cords and including the trachea, bronchi, bronchioles, and countless alveoli of the lungs. The 70 m^2^ ([@bib170]) surface area of the human respiratory tract is inhabited by the microbiota, differing in quantities and qualities along the tract in response to niche-specific conditions ([@bib103], [@bib79]). The movement of air and particles, including microbiota, in the respiratory system is bidirectional. The composition of the lung microbiome in each site is thus a consequence of the balance reached between migration to the airways, elimination from the airway, site-specific immune processes (e.g., presence or absence of inflammation) and the growth rates of the microbes ([@bib79]). Highlighting the role of the URT as a gatekeeper to respiratory health ([@bib103]), microbiota enter the lung mainly via microaspiration from the nasopharynx and the more densely and diversely populated oropharynx. Microbes can also enter the lung via dispersion along the mucosal surface ([@bib16], [@bib49]).

Bacteria of the healthy URT include the genera *Staphylococcus, Propionibacterium, Dolosigranulum, Corynebacterium, Moraxella, Streptococcus, Haemophilus, Rothia, Veillonella, Prevotella,* and *Leptotrichia* ([@bib185], [@bib60], [@bib175]). In addition to bacteria, several viruses and fungi have been found in the URT of healthy people. Human rhinovirus (RV), bocavirus, adenovirus, coronavirus, polymavirus, and Anneloviridae family viruses have been identified in the URT of large proportions of healthy asymptomatic children using PCR-based methods and metagenomics, even in geographically isolated locations ([@bib161], [@bib19], [@bib177], [@bib6]). Detection frequency of these viruses in many studies is not different in the URT of asymptomatic controls and children hospitalized due to the respiratory tract infections, in contrast to respiratory syncytial virus (RSV), human metapneumovirus (hMPV), parainfluenza viruses (PIVs), and influenza, being causally associated with hospitalizations, lower respiratory symptoms, and pneumonia ([@bib139], [@bib133], [@bib17]). These data suggest that in the cases of these "commonly carried" URT viruses, not only their presence, but rather total viral load ([@bib83]) or complex interactions between viruses and bacteria ([@bib161]) or other environmental (e.g., allergen) and intrinsic host factors (e.g., sensitization) ([@bib131]) determine the occurrence of disease in the URT or LRT. Interestingly, in healthy adults these viruses are detected less frequently than in asymptomatic children, suggesting age-dependent and perhaps ecosystem-dependent changes in viral load of the URT ([@bib151]). *Aspergillus, Penicillium, Candida,* and *Alternaria* are fungal genera found in the URT of healthy people ([@bib32]).

In the healthy lungs of the LRT, there are six dominant bacterial phyla: Firmicutes (including genera *Streptococcus* and *Veillonella*), Bacteroides (including genus *Prevotella*), Proteobacteria, Fusobacteria, Acidobacteria, and Actinobacteria (including *Tropheryma whipplei*) ([@bib135], [@bib48], [@bib49]). The virome of the healthy lungs contains members of the Anelloviridae family and a high frequency of various bacteriophages ([@bib2], [@bib173], [@bib82]), but their abundance is greater in the context of immunosuppression ([@bib180]) and/or chronic disease ([@bib61]), suggesting that immunocompetence is a prerequisite to the low abundance and biodiversity of LRT virome. The lung mycobiome is composed of *Eremothecium*, *Systenostrema*, and *Malassezia* genera and the Davidiellaceae family ([@bib32], [@bib163]).

The majority of cited studies have used genetic techniques to identify microorganisms' taxa, and the results were not usually confirmed by culture-dependent methods. However, sequencing allows identification of more diverse microbes and is not limited by the viability or ability to grow the microorganisms *in vitro* ([@bib48]). Most studies underscore that the healthy microbiome is rather transient in the lungs at steady state. In contrast, during disease, when inflammatory conditions enable the growth of certain bacteria, it can lead to dysbiosis and subsequent colonization with pathogens.

The healthy microbiome of the URT and LRT plays several important roles in the development and maintenance of homeostasis of the RT and whole organism. The composition of the microbiome at all mucosal sites changes dynamically from the first days of life, shaping the establishment of proper interactions between the microbiota and human body and constituting the critical "window of opportunity" for determining future health or disease ([@bib116], [@bib115], [@bib146]). Directly after birth, the skin, gut, nasopharynx, and mouth microbial communities are undifferentiated and colonized by bacterial species reflective of delivery mode ([@bib42]). During birth and in the first days of life, maternal vaginal and skin microbiota only transiently transfer to the infant, whereas the mother's gut microbiota becomes the primary source of microbial strains acquired by the baby by the age of four months ([@bib57], [@bib179]). The separation between the URT and LRT in the context of early life is important as these two anatomical sites represent different habitats. The URT experiences constant exposure to the external environment and its accompanying conditions from the first moment of life, which shapes the URT microbiota. However, it has been demonstrated that by 24 h after birth bacterial DNA can be detected in the LRT of neonates ([@bib178]). The transient nature of the LRT microbiota at the steady state is determined by the balance between microbiota that enter from the URT and microbiota that are eliminated by host immunity; therefore, URT samples cannot fully reflect on the interactions that occur in the LRT ([@bib178]). The healthy respiratory tract microbiome plays also important roles in conferring colonization resistance. The term "colonization resistance" refers to the ability of a healthy and timely microbiota to actively suppress or compete with pathogens to inhibit their outgrowth, as has been shown *in vitro* ([@bib20]) and *in vivo* ([@bib43], [@bib81]).

The overall influence of the healthy airway microbiota on host immunity reflects cumulative effects of live microbes and components of their cells or metabolites on local and systemic innate and adaptive immune processes in the host ([@bib135], [@bib169]). If the process of healthy and timely colonization is disrupted, early-life dysbiosis of the gut and lung microbiota becomes an important risk factor for the development of many respiratory diseases ([@bib18], [@bib156]). The mechanisms involved likely operate at different modes e.g., via inadequate training of host immunity ([@bib66]), inefficient colonization resistance ([@bib43]), and/or improper lung morphogenesis ([@bib182]). During *in utero* development and later in life, there are several direct and indirect factors that affect healthy microbiota colonization and subsequent host-microbiota interactions. These factors include mother's health status ([@bib147]), diet ([@bib62], [@bib13]), transfer of maternal antibodies and microbial molecules ([@bib67], [@bib89]), mode of delivery ([@bib21]), and breastfeeding and early-life environment (day care, siblings \[[@bib174]\], pets at home \[[@bib140], [@bib159]\], traditional farm-like dust at home \[[@bib144], [@bib88]\], and smoking and antibiotic and other drug usage in pregnancy and early childhood \[[@bib109], [@bib98]\]).

Gut-Lung Axis Impacts on Respiratory and Gut Health {#sec1.3}
---------------------------------------------------

The human gut starts at the oral cavity, continues through the esophagus, stomach, small intestine, colon, and ends at the rectum. Its 150--200 m^2^ enormous surface area provides microbes opportunities for colonization or transient occupation. Indeed, the human gut is inhabited by between 100 thousand and 100 billion bacteria per mL of luminal content depending on the region and therefore is the most densely colonized organ ([@bib136]). Bacteria within the gut confer several functions to the host, including vitamin production, absorption of ions, protection against pathogens, histological development, enhanced immune functions, and fermentation of food ([@bib74]). They are typically dominated by five phyla; Bacteroidetes, Firmicutes, Proteobacteria, Actinobacteria, and Tenericutes ([@bib47], [@bib4]), whereas *Bacteroides*, *Faecalibacterium*, and *Bifidobacterium* are the most prevalent genera in healthy adults ([@bib105]). The oral cavity is mainly colonized by bacteria from the Streptococcaceae, Pasteurellaceae, Veillonellaceae, Prevotellaeace, and Neisseriaceae families and *Gemella* genus; the stomach mostly contains bacteria from the Lactobacillaceae family; the small intestine is dominated by Lactobacillaceae, Enterobacteriaceae, and Streptococcaceae; and the most densely colonized large intestine contains bacteria from the families of Enterococcaceae, Clostridiaceae, Enterobacteriaceae, Bacteroidaceae, Bifidobacteriaceae, Fusobacteriaceae, Lactobacillaceae, Peptostreptococcaceae, Peptococcaceae, Prevotellaeace, Lachnospiraceae, Ruminococcaceae, Rikenelleace, and the phylum Verrucomimicrobia ([@bib74], [@bib118]). *Candida*, *Saccharomyces*, *Malassezia*, and *Cladosporium* are among the most commonly and consistently identified fungal genera in human gut mycobiota studies ([@bib76], [@bib148], [@bib10], [@bib101], [@bib80]). Besides bacteria and fungi, the human gut microbiota is additionally composed of viruses (primarily phages) and archaea (mainly *Methanobrevibacter smithii)* ([@bib99]).

A connection between the lungs and gut has been repeatedly demonstrated in both human and mouse studies. Inducible bronchus-associated lymphoid tissue (iBALT) and gut-associated lymphoid tissue (GALT), which are part of the mucosal-associated lymphoid tissue, are related in morphology and function, which includes the regulation of local immune responses ([@bib53]). The main immunological functions of GALT and iBALT include production and secretion of IgA at mucosal surfaces, as well as Th cell and cytotoxic (Tc) responses ([@bib30]). Regulation of local immunity in GALT occurs in Peyer's patches and mesenteric lymph nodes. Terminal transformation of B cells to plasma cells able to secrete antibodies is finalized in the lamina propria, where memory and effector T and B cells reside. Importantly, 80% of activated B cells in adults are found in gut mucosal tissue ([@bib24]).

The concept of the gut-lung connection was born out of the observation that different lung diseases can be influenced by intestinal microenvironment changes and vice versa. The microbiota is an important factor responsible for interactions between these two sites in asthma ([@bib105]). In addition, the gut microbiota of patients with severe bacterial pneumonia ([@bib36]), cystic fibrosis ([@bib105]), and influenza differs from that of healthy controls ([@bib123]). Many studies show that early life is the most important period during which microbiota dysbiosis in the gut may lead to the development of many respiratory diseases, as the gut microbiota has a significant influence on immune cell maturation and resistance to pathogens ([@bib143]).

The mechanisms mediating communication between the gut and lungs are still unclear, but it has been suggested that epithelial cells, other structural cells, and immune cells absorb signals from the endothelium to form a local cytokine microenvironment, which leads to changes in immune responses at distal sites ([@bib25]). Naive immune cells initially activated in the gut travel via lymph and blood vessels to the lung, where they have effector functions ([@bib71]). Importantly, the local immune reaction in GALT and iBALT can influence systemic immune responses but the mucosal immune system can also act independently of the systemic site ([@bib30]). Interestingly, emerging evidence indicates that the gut-lung axis is bidirectional. For instance, stimulation of mouse lungs with lipopolysaccharide (LPS) causes a significant increase in the number of bacteria in the gut ([@bib152]), and it has been shown that pneumonia induces intestinal injury ([@bib120]) and decreases gut epithelial proliferation ([@bib38]) ([Figure 2](#fig2){ref-type="fig"} ).Figure 2Gut-Lung Axis in Lung Inflammation ContextA connection between lungs and gut has been repeatedly demonstrated in both human and mouse studies. Many studies show that the microbiota is an important factor responsible for the interactions between these two sites. The interaction can be bidirectional; the gut microbiome can influence immune responses in lungs and lung stimulation can result in gut responses.

In addition, the gut-lung-liver axis has been described in COPD ([@bib181]). Short-chain fatty acids (SCFAs) derived from gut bacteria have inhibitory effects on proinflammatory responses in the lungs. One of the proposed mechanisms is that the liver can dampen the innate immune response by SCFAs binding to G-protein receptors or inhibiting the mevalonate pathway through HMGCoA reductase ([@bib181]). Furthermore, in a mouse model of pneumonia, it has been shown that cytokine expression in airspace macrophages was dependent on acute-phase protein (characteristic for hepatic acute-phase response) extravasation into the alveoli. These data suggest that the liver response enhances macrophage activation and pulmonary inflammation ([@bib73]).

Bacteria Are the Largest Microbial Population in the Gut and Lungs {#sec1.4}
------------------------------------------------------------------

As the human gut is the most densely colonized site of the human body ([@bib136]), its community of bacteria and their correlations with asthma both in early life and during established disease require special attention ([@bib77]).

*Lachnospira*, *Veillonella*, *Faecalibacterium*, and *Rothia* genera are significantly decreased in relative abundance in fecal samples of three-month-old Canadian children at high risk of asthma. This bacterial signature is no longer evident at age 1 year and is accompanied by reduced amounts of fecal acetate and dysregulation of enterohepatic metabolites. Moreover, predicted bacterial community function analysis shows a reduction of LPS biosynthesis pathways in the microbiota of children at high risk of asthma ([@bib9]). In an ovalbumin (OVA)-induced mouse model of airway inflammation, supplementation of a fecal slurry from an infant who developed asthma transplanted into germ-free mice with representative species from *Lachnospira*, *Veillonella*, *Faecalibacterium*, and *Rothia* genera decreased airway inflammation ([@bib9]). In another human birth cohort study, Ecuadorian children with an increase in the relative abundance of *Streptococcus* and *Bacteroides* species and decrease in *Bifidobacterium* species and *Ruminococcus gnavus* in fecal samples at 3 months of age have a higher risk of developing atopy and wheeze at age 5 years ([@bib8]). Finally, among neonates from the United States grouped into three clusters according to the composition of the gut microbiota, those with the lowest relative abundance of *Bifidobacteria*, *Akkermansia*, and *Faecalibacterium* genera and a higher relative abundance of *Candida* and *Rhodotorula* fungi have the highest risk of developing atopy and asthma ([@bib63]) ([Figure 3](#fig3){ref-type="fig"} ).Figure 3Bacteria, Fungi, Viruses, and Archaea in the Lungs and Gut that Dysbiosis Has the Influence on Asthma Development and Maintenance

The effects of the gut microbiota on asthma are at least partially mediated by bacterial metabolites, which may influence immune responses in distal parts of the body. The most known metabolites with demonstrated protective properties in human airway inflammation are SCFAs. Children with high amounts of butyrate and propionate in feces at 1 year of age have significantly less atopic sensitization and are less likely to have asthma between 3 and 6 years ([@bib128]). Moreover, soluble fiber supplementation has been found to decrease sputum eosinophilia and sputum histone deacetylase 9 gene expression in asthma patients ([@bib106]). In mice, SCFAs have been shown to increase the expression of the transcription factor FOXP3 via inhibition of histone deacetylation, thereby supporting the expansion of T regulatory cells (Tregs), and increasing the production of IL‐10 ([@bib7]). SCFAs have also been shown to reduce inflammation in both OVA and house dust mite (HDM)-induced airway inflammation models ([@bib158], [@bib27]). Moreover, oral application of SCFAs to mice during pregnancy and weaning have protect offspring from allergic lung inflammation, with butyrate in particular potently inducing Tregs in the lungs of offspring ([@bib128]) ([Figure 2](#fig2){ref-type="fig"}).

Of recent interest are studies showing that gut bacteria in humans are able to produce other metabolites with pro- and anti-inflammatory potential, such as biogenic amines (including histamine) ([@bib122]) and oxylipins such as 12,13-diHOME ([@bib93]). The number of histamine-secreting bacteria is significantly higher in fecal samples of asthma patients compared with non-asthmatic volunteers ([@bib14]). In addition, the number of histamine-secreting bacteria correlates with disease severity. However, in a model of OVA-induced allergic airway inflammation, bacteria-derived histamine decreased total cell number in the bronchoalveolar fluid (BAL) and amounts of IL-4, IL-5, and IL-13 in lung homogenate ([@bib14]), highlighting the complexity of bacteria-derived immune regulation. Conversely, intra-abdominal treatment of mice with 12,13-diHOME decreased the number of Treg cells in the lungs and increased pulmonary inflammation in a cockroach antigen mouse model of airway inflammation ([@bib93]) ([Figure 2](#fig2){ref-type="fig"}). The metabolites secreted by lung and gut bacteria might prove useful for additional therapeutic approaches.

In the lungs, Proteobacteria appear repeatedly to be the most dominant phylum overrepresented in patients with asthma compared with non-asthmatic volunteers across several human studies ([@bib78], [@bib104], [@bib183], [@bib75]). The Proteobacteria phylum is represented by potentially pathogenic bacteria, including those that belong to the genera *Haemophilus*, *Moraxella*, and *Neisseria* ([@bib78], [@bib29]).

Within asthmatic inflammatory phenotypes, patients with neutrophilic asthma, usually receiving high doses of inhaled corticosteroids (ICSs), demonstrate a less diverse bacterial load with relative enrichment in *Haemophilus* and *Moraxella* species, members of Proteobacteria phylum, and a reduction in the relative abundance of *Streptococcus*, *Gemella*, and *Porphyromonas* taxa compared with patients with eosinophilic asthma ([@bib155], [@bib138], [@bib68]). In patients with severe asthma, a Th17 cell epithelial gene signature representing the non-type 2 asthma has been associated with increased representation of the phylum Proteobacteria, which further correlates with worsening of asthma control ([@bib78]) and neutrophilic exacerbations of asthma ([@bib64]). *Klebsiella* is one genus of bacteria within the Proteobacteria phylum enriched specifically in patients with severe asthma, whereas the phylum Actinobacteria correlates with improvement or no change is asthma control. Indicating the complexities of identifying cause-and-effect relationships, changes to microbial communities in the lungs may also result from asthma therapies. Actinobacteria, for instance, was associated with molecular evidence of response to steroids (FKBP5 expression) ([@bib78]). Certain airway microbiota may therefore have the potential to be used as indicators of asthma responsive to steroids, allowing clinicians to refine the therapies. Importantly, the substantial additive effects of obesity and asthma severity on host immunological responses and the airway and gut microbiota have been recently described. Both obese and non-obese asthma patients with severe disease have reduced fecal levels of *Akkermansia muciniphila*, which may have a causal relationship as shown in murine models of acute and chronic airway inflammation ([@bib188]). Another genus present in the lungs of patients with severe asthma is *Streptococcus* ([@bib183], [@bib26]).

Subjects with atopic asthma, usually of the eosinophilic inflammatory phenotype, demonstrate enrichments in bacteria from the genera *Fusobacterium* and *Porphyromonas* and the Sphingomonodaceae family, and decreased relative abundance of members of Mogibacteriaceae family and Lactobacillales order. ([@bib51]). In addition, eosinophils in the sputum of asthma patients have been connected with the presence of *Tropheryma whipplei* in human adults ([@bib138]). In contrast to surprisingly reproducible findings in neutrophilic asthma, the status of the microbiota in eosinophilic and type 2 asthma is less clear and more heterogeneous, potentially reflecting again the differences in underlying endotypes or mixed responses caused by ICS treatment.

It currently remains unclear to what extent the diversity and presence of specific bacteria in the airways of adult patients with asthma reflects the type of inflammation or the microbial response to corticosteroid treatment. It has been demonstrated that treatment with a combination of ICSs and oral glucocorticoids correlates positively with an increased abundance of Proteobacteria and *Pseudomonas*, and with a decreased abundance of *Bacteroidetes*, *Fusobacteria*, and *Prevotella* ([@bib45]). On the other hand, a study in mild asthmatics not treated with ICSs has demonstrated a unique enrichment in members of the *Haemophilus*, *Neisseria*, *Fusobacterium*, and *Porphyromonas* species and the Sphingomonodaceae family with concurrent depletion in members of the Mogibacteriaceae family and Lactobacillales in their airways ([@bib51]). Together these studies suggest that the lung microbiome composition in patients with asthma, who are often treated with corticosteroids, is probably a result of complex interactions between the inflammatory milieu and the drug effects.

Infection of mice with *Moraxella catarrhalis* (*M. catarrhalis,* Proteobacterium phyla) results in neutrophilic infiltrates, high concentrations of IL-6, IL-1β, and tumor necrosis factor α (TNF-α), and moderate concentration of CD4^+^ T cell-derived IFN-γ and IL-17 in the lungs 1 day after infection. Moreover, neutralization of IL-17 or TNF-α, but not IL-6, results in accelerated clearance of *M. catarrhalis* and effectively prevent infection-induced exacerbation of allergic airway inflammation ([@bib5]). Furthermore, *Haemophilus influenzae* from Proteobacteroium phyla is able to convert steroid-sensitive allergic airway disease (AAD) associated with Th2 cells and eosinophils to steroid-resistant disease associated with Th1 cells, neutrophils, and dominant IL-17 responses ([@bib55]).

An increasingly large body of evidence suggests a role for bacteria in asthma, but further studies are needed to more clearly define the most important species involved and to understand whether bacterial dysbiosis in the context of asthma is the cause or effect of disease. More detailed mechanistic studies are necessary to gain full understanding of the complex associations of lung and gut microbiota compositions and metabolism at different points in life with specific types of asthmatic inflammation. Even if some immunological mechanisms of early-life protection have been described, there are probably many others. In addition, the immunological and molecular mechanisms of already established dysbiosis in adult asthma need to be characterized in more detail, ideally to reverse these processes. Moreover, further attention should be paid to understanding the connection between a patient's microbiome and response to asthma therapies, as these may influence one another. Microbial-derived mechanisms might be the reason of poor response to the treatment, as it has been elegantly demonstrated in vaccination ([@bib69]). Finally, future work should focus on continuing to characterize in detail the cellular and molecular mechanisms mediating communication between bacteria and the host in asthma.

Looking beyond Bacteria: Fungi: The Forgotten Microbes {#sec1.5}
------------------------------------------------------

Important groups of microbes, which together comprise the "rare biosphere" ([@bib100], [@bib85]) of the microbiota, include fungi and other micro-eukaryotes. It remains unclear whether fungi colonize the healthy adult gut or are simply detected in sequencing studies as transient oral or food-derived fungi ([@bib10]), but even transient colonizers of the gut have the potential to impact microbial community ecology and host immune responses ([@bib70]). Although the mechanisms involved were not explored, two recent studies in human birth cohorts from the United States and Ecuador have identified fungal dysbiosis as a key feature of infant gut microbiota signatures associated with the development of high-risk asthma phenotypes in childhood ([@bib63], [@bib8]). The specific signatures of fungal dysbiosis associated with asthma and related phenotypes differed in these studies, but it is notable that fungal dysbiosis was much more striking than bacterial dysbiosis in both studies. These results suggest that fungal dysbiosis may be a readily detectable biomarker of asthma risk. Moreover, both studies found that fungal dysbiosis co-associated with bacterial dysbiosis ([@bib63], [@bib8]), calling for follow-up studies investigating both the microbial and immune mechanisms underlying these associations.

Microbes within the gut influence host immune responses to other microbes, interact physically and metabolically with one another, and compete for space and nutrients. Early studies in animal models aimed at establishing a causal link between fungal dysbiosis and asthma severity demonstrated that mice pre-treated with antibiotics are susceptible to fungal overgrowth following oral gavage with the common human gut commensal *Candida albicans* (*C. albicans*) ([@bib113], [@bib111]). These mice further demonstrate exacerbated Th2 cell-mediated airway inflammation following airway challenge ([@bib113], [@bib111]), an effect postulated to be mediated at least in part by the production of immunomodulatory prostaglandins by *C. albicans* ([@bib114], [@bib54]). Congruent with this, overgrowth of another *Candida* species, *C. parapsilosis*, in the murine gut following antibiotic treatment has more recently been linked to prostaglandin PGE~2~-mediated polarization of lung macrophages to the M2 phenotype and exacerbated allergic inflammation following antigen sensitization and challenge. In this model, fungal overgrowth is correlated with inflammatory immune cell infiltration to the lung but also required specific antibiotic-induced changes to the bacterial microbiota. Only antibiotics causing reductions in the relative abundance of bacteria from the genus (among others) *Lactobacillus* are associated with fungal overgrowth and exacerbated airway inflammation following antigen challenge ([@bib186]). Notably, *Lactobacillus* and other lactic acid-producing bacteria are of interest for their use as a probiotic to protect against asthma and allergy ([@bib58]) and have known anti-fungal effects ([@bib134], [@bib112]).

Further evidence that the historical and current microbial context within which fungal dysbiosis occurs influences the associated immunological consequences during asthma has emerged more recently. Mice with no pre-existing mycobiota demonstrate a mixed Th2 and Th17 cell lung infiltrate following inoculation with a dysbiotic fugal community, whereas the same treatment in conventional mice with a pre-existing mycobiome results only in increased Th2 cell inflammation during asthma ([@bib96]). Similarly, fungi-naive mice newly colonized with *C. albicans* demonstrate exacerbated AAD associated with systemic expansion of fungus-specific Th17 cells and IL-17-hyperresponsive neutrophils ([@bib137]). Together these studies highlight the complex, dynamic nature of the gut microbiota and the importance of cross-kingdom microbial interactions in determining asthma outcomes.

In addition to antibiotic treatment, antifungal treatment induces changes to both the bacterial and fungal communities in the gut of specific pathogen-free (SPF) mice and has been shown to exacerbate type 2 allergic airway inflammation and eosinophilia in a HDM model of AAD ([@bib172], [@bib96]). Continuous supplementation with three fungal species identified in this model to be overrepresented in the gut following antifungal treatment (*Aspergillus amstelodami*, *Wallemia mellicola* \[*sebi*\], and *Epicoccum nigrum*) ([@bib172], [@bib96]) or with *Wallemia mellicola* alone following antibiotic treatment ([@bib141]) similarly increases asthma severity ([Figure 3](#fig3){ref-type="fig"}) ([@bib172], [@bib141]). Antifungal treatment and the introduction of dysbiotic fungal communities to SPF mice in these studies results in changes to gut bacterial communities, including depletions of bacteria from the Lactobacillaceae family ([@bib96], [@bib141]). However, the AAD-exacerbating effects of supplementation with a dysbiotic fungal community can be recapitulated in altered Schaedler flora mice without pre-treatment with antibiotics and in the absence of substantial changes to the bacterial microbiota ([@bib96], [@bib141]). Furthermore, [@bib96] recently demonstrated that direct sensing of antifungal-induced fungal dysbiosis by gut-resident CX3CR1^+^ mononuclear phagocytes ([@bib92]) increases numbers of Th2 cells in the lamina propria and is responsible for fungal dysbiosis-associated increased airway inflammation in a HDM model of AAD, independent of antifungal-associated changes to the bacterial communities ([@bib96]). Thus, in addition to having potential indirect effects on airway inflammation via restructuring of immunomodulatory gut bacterial populations or the production of systemic metabolites, asthma-associated fungal dysbiosis in the gut can have direct effects on host innate and adaptive immune cell populations.

Local fungal dysbiosis in the lung has also been linked to asthma in several studies in humans. It has been shown in a small sample of subjects that children with and without severe asthma exhibit differences in the relative abundance of specific fungi, but not overall fungal diversity, in BAL samples. These differences included increases in the relative abundance of *Pneumocystis* in the lungs of patients with severe asthma ([@bib65]), a microbe whose presence within the lungs has been linked to the induction of host type 2 immune responses in humans and animal models ([@bib52]). Subclinical colonization of the lungs with *Pneumocystis* at 2--5 months of age has been suggested to be one of the most common infections in infancy ([@bib165], [@bib167]) and is associated with increased mucin gene expression ([@bib119], [@bib165], [@bib167], [@bib166], [@bib129]). Early lung colonization with *Pneumocystis* may therefore represent a risk factor for the induction of Th2 cell-skewed immune responses in the lung and predispose infants to asthma ([@bib129]).

An 18S pyrosequencing study in adult patients similarly found that, compared to non-atopic controls, patients with asthma demonstrate differences in the relative abundance of specific fungi in pooled sputum ([@bib163]). In these adults, those with asthma demonstrate an increase in the relative abundance of species of *Malassezia* previously linked to the allergic condition of atopic dermatitis ([@bib163]). Overall, a picture is emerging wherein patients with asthma exhibit an increase in the relative abundance of specific fungi associated with the induction of type 2 inflammatory immune pathways, some of which are either absent or present only in low abundance in the healthy lung.

Findings of altered fungal populations in the lungs of asthmatic patients are not surprising, as fungal components such as mannans, proteases ([@bib121]), chitin, and β-glucans ([@bib162]) are often found in common human allergens and house dust. While the underlying mechanisms of sensitization remain unclear, many patients with severe and/or uncontrolled asthma are sensitized to fungi ([@bib46], [@bib145], [@bib59]) and/or may show improvements in asthma symptoms following antifungal therapy ([@bib34], [@bib46]). Lung fungi commonly associated with sensitization and asthma include those from the genera *Aspergillus*, *Alternaria*, and *Cladosporium* ([Figure 3](#fig3){ref-type="fig"}) ([@bib46], [@bib59]). Interestingly, some evidence from animal models suggests that sensitization occurs secondary to the natural Th2 cell and eosinophilic immune response required for effective clearance of infection-causing fungi ([@bib121]). Additionally, increased fungal load in BAL samples has been associated with corticosteroid therapy in patients with severe asthma with and without fungal sensitization ([@bib59]). Thus, future work is needed to determine whether pathological fungal colonization and mycological dysbiosis of the lungs causes the onset of more severe asthma and occurs subsequent to severe asthma-associated corticosteroid treatment, and/or in response to asthma-associated changes in the lung microenvironment.

More recently, studies have begun to precisely characterize the airway mycobiota associated with certain asthma endotypes and clinical features. In a study examining the microbiota of endotracheal brushings and BAL fluid, *Fusarium*, *Cladosporium*, and *Alternaria* ([Figure 3](#fig3){ref-type="fig"}) species were among the fungal organisms identified to be enriched in the BAL of patients with asthma and type 2 high asthma relative to healthy controls and patients with type 2 low asthma, respectively ([@bib187]). Indicating their potential for use as biomarkers of disease, the relative abundance of *Alternaria* and *Cladosporium* in BAL fluid has also negatively associated with forced expiratory volume 1, a clinical measure of lung function (Sharma et al., 2019).

Over the past couple of decades, there has been an explosion of research into the composition and immunological effects of non-bacterial members of the gut microbiota, including fungi, on the host. Although much remains to be elucidated, a robust body of evidence now supports a substantial role for fungi in the dysbiosis-asthma paradigm. Fungal-bacterial and fungal-host interactions both play an important role in determining the effects of fungal dysbiosis on host health. Much of this work has been done in pediatric birth cohorts and mouse models, calling for more studies into the relevance of the gut mycobiota to asthma in human adults. Furthermore, if and how early-life fungal dysbiosis influences the onset and/or severity of asthma later in life when the dysbiosis may no longer be present remains to be mechanistically tested.

Virions Readily Colonize the Lungs {#sec1.6}
----------------------------------

Although viral infections are known to be a primary cause of asthmatic exacerbations, the relationship between viruses and asthma is not completely understood, partly because of continuously evolving knowledge about the healthy virome of the respiratory tract. It has been observed that the composition and abundance of the URT and LRT virome differs among healthy subjects and asymptomatic and symptomatic patients with chronic respiratory diseases, but detailed longitudinal studies are needed for better comprehension of the causal relationships ([@bib151], [@bib61]). Complex interactions between viruses and additional environmental and intrinsic factors are probably responsible for the longer but transient presence of some viruses in the respiratory tract of asthmatic patients or the development of fully blown infections leading to severe exacerbations ([@bib164], [@bib133]).

In the first years of human life, almost all wheezing episodes are correlated with viral infections ([@bib108]). The most common viruses known to induce wheeze or exacerbations of asthma are RV and RSV, but bocavirus, influenza virus, and cytomegalovirus (CMV) ([Figure 3](#fig3){ref-type="fig"}) have also been implicated ([@bib107], [@bib108]). It has been reported that early-life RV-induced wheezing has additive effects on asthma risk later in life.

The most abundant cell type in the airways of infants with RV bronchiolitis is neutrophils, although infiltration of eosinophils also plays an important role ([@bib72]). Moreover, it has been recently demonstrated that concentrations of mast cells IL-6, IL-8, TNF-α, and IFN-α was significantly higher after stimulation with RV ([@bib97]). T cells participate in controlling RV infection through the recognition of viral antigens and subsequent initiation of both Tc and antibody-mediated immune responses ([@bib72]). Of particular interest is a recent study showing *in vitro* that RV enters and forms viral replication centers in B lymphocytes and induces the proliferation of B cells ([@bib1]).

Another virus linked with increased risk of asthma is RSV ([@bib11]); however, its association with the disease is less clear ([@bib86]). There are studies suggesting a connection between RSV-induced bronchiolitis and asthma ([@bib11]), but others have not identified a correlation between RSV infection in infants and the development of asthma at school age ([@bib176]). The long-term influence of RSV infection on asthma can be connected with fact that the virus typically affects neonates during lung development ([@bib84]). Neonatal regulatory B cells are highly permissive to RSV infection, and the frequency of this cell population can predict the severity of acute bronchiolitis ([@bib184]). Moreover, RSV rapidly adheres to human eosinophils and might be inactivated by these cells. The capacity of eosinophils to capture virus is reduced up to 75% with increasing severity of asthma ([@bib132]).

Influenza viruses are another viral infections connected with asthma exacerbations ([@bib41]). Asthma in the setting of influenza infection is associated with worse severity, higher risk of hospitalization, need for intensive care, and mortality ([@bib127]). IL-33 has been hypothesized to be necessary for driving influenza virus-induced asthma exacerbations. In a mouse model of asthma, IL-33 enhanced airway hyperresponsiveness and airway inflammation by suppressing innate and adaptive antiviral responses ([@bib125]). Another study has shown that influenza infection induced airway hyper-reactivity through a pathway that required the IL-13-IL-33 axis ([@bib31]).

Besides the most well-studied viruses linked to asthma and described above, there are also a few less commonly encountered viruses that influence airway inflammation involved in asthma. Human bocavirus 1 (HBoV) and CMV are also connected with wheezing episodes in children. A study published by [@bib44] reported that, in a small sample of children with HBoV aged ≥4 years who were previously hospitalized due to acute bronchiolitis, all of them developed recurrent wheezing, and half of them had asthma at age 5--7 years. It has been also demonstrated that subcutaneous injection of HBoV-VP1u or B19V-VP1u proteins in OVA-sensitized mice resulted in elevated airway inflammation ([@bib33]). Finally, CMV DNA was detected in 51.4% of patients with recurrent wheeze and was more prevalent among those aged 12--36 months with a positive modified asthma predictive index (mAPI) than in those of the same age group with a negative mAPI ([@bib150]).

The connection between respiratory viral infections and asthma development has been recently investigated using more mechanistic approaches ([@bib102], [@bib157]). However, the precise mechanisms responsible for the correlation are still unclear and need further detailed investigations in animal models as well as in human studies using multi-omics approaches ([@bib142]). Analyses considering the global virome of patients should also be considered in the future. Finally, scientists should also ask the question: is it possible that gut viruses can influence lung inflammation?

Archaea-Emerging Players in Human Gut {#sec1.7}
-------------------------------------

Although understudied, archaea are consistently identified in human microbiota studies and their community composition differs according to body site ([@bib90]). Methonoarchaea, including *Methanobrevibacter smithii* and *Methanosphaera stadtmanae (M. stadtmanae)*, have been proposed as keystone members of this microbial community and possess immunogenic properties ([@bib94], [@bib12]).

A role for intestinal archaea in the dysbiosis-asthma paradigm was recently suggested by a study in a subset of 472 children from the KOALA birth cohort in the Netherlands ([@bib15]). The presence of *M. stadtmanae* in stool samples from 6- to 10-year-old children has been associated in a dose-dependent manner with a reduced risk of being diagnosed with asthma ([@bib15]). This effect was independent of parental asthma status ([@bib15]). Only 8.3% of samples tested in this study were positive for *M. stadtmanae*, however, and certain archaeal proteins have actually been proposed to have pro-inflammatory ([@bib94]) or allergenic properties ([@bib23]). Thus, more cohort studies and mechanistic studies into the immunomodulatory effects of gut archaea in the context of asthma are needed. As in the case of the other microbial communities discussed in this review, the microbial and immune context within which disrupted archaeal communities occur likely determine the ultimate immunological consequences for the host. Furthermore, as the human lung microbiota in childhood and adults continues to be characterized, the role of lung archaea in the dysbiosis-asthma paradigm will need to be determined.

Conclusions and Future Perspectives {#sec1.8}
-----------------------------------

It is now supported by a rich body of literature that the human microbiota influences the maturation and function of the host immune system. Both lung and gut microbiota have impacts on asthma development, phenotype, and severity, but the detailed cellular and molecular mechanisms of these correlations have not yet been fully characterized. One important tool that will be helpful to understand mechanisms underlying the connection between the human microbiota and the immune system is humanized microbiota mouse models for allergic airway inflammation. Special attention should also be given to improving *in vivo* animal models to establish studies that mimic human clinical conditions as closely as possible. Currently, there are only two common mouse models of allergic airway inflammation: OVA and HDM-induced acute models, which reflect mainly type 2 asthma. Other models, utilizing high allergen doses or LPS, *Chlamydia muridarum*, *Haemophilus influenzae*, paramyxovirus, or RV1, usually in addition to allergen, partially reflect non-type 2 inflammation and should be used to complement OVA and HDM models ([@bib153], [@bib87]).

Thanks to advances in DNA and RNA sequencing technologies, it is now possible to characterize many unculturable microbial strains that were not known to be associated with asthma conditions just a few years ago. Recent analyses using currently available sequencing methods have allowed us to determine that microbial dysbiosis of the gut and lungs in airway inflammation is characterized by taxa-specific shifts in abundance at the family, genus, species, and even strain levels. These data clearly show that future studies should be more concentrated on specific changes of microbiota taxonomy, including strain differences, rather than at overall changes. On the other hand, global views of the microbiota and its correlations with host phenotypes should be taken into consideration. Studying isolated bacterial strains in the context of airway inflammation might have very different outcomes than if the same strains were investigated within a bacterial community. Moreover, more emphasis should be given to the detailed study of different parts of the human microbiota, including viruses, archaea, fungi, bacteriophages as well as parasites, and the possibility of global shifts or changes to inter-kingdom or inter-site microbial interactions within the microbiota in the context of asthma.

Moreover, it is well established that the distribution of microbiota differs according to physico-chemcial niches in the gut. The study of gut microbial compositions in mice and their correlations with airway inflammation should therefore take into consideration gut biogeography. The most common approach to analyzing the gut microbiota is analysis of the fecal microbiota while ignoring the microbes that remain along the gastrointestinal tract. This approach may lack important information and potential misinterpretation of the connection between the gut microbiota and host and is a limitation of most current studies.

Asthma is very complex disease characterized by many different phenotypes and endotypes. Human cohort studies should therefore include clearly defined clinical outcomes and collect longitudinal data from detailed and specified questions about symptoms, treatments, and clinical information. Complete information regarding patient diet and lifestyle should also be carefully prepared to ensure the best overview of patient conditions and potential influences on the microbiota. Future studies should be extended to include several time points during a patient's life to determine whether changes to the earlier-life microbiota are connected to asthma development or preventions, or to an increase or improvement in airway inflammation. Importantly, longitudinal and prospective analyses of larger cohorts of patients are needed to understand the relationships between the course of the disease, its phenotype and endotype, susceptibility to disease progression, and response to treatment. Finally, considerable attention has and continues to be paid to early-life changes to the gut and lung microbiota and their influence on allergy symptoms later in life. While it is indisputable that early life is a very important period during which microbiome dysbiosis may lead to the development of immune-mediated diseases, we should also be able to answer the question: is it still possible to change, through modulation of the microbiota, allergic disease conditions later in life even if the early-life period was neglected?

To summarize, it is clear that the future diagnosis and treatment of patients with asthma should be assisted by analysis of the composition and metabolic activity of an individual's microbiome. Clinical studies of new therapeutics should consider including microbiome and metabolite analyses to determine whether microbiome features correlate with responses to treatment. Further mechanistic and epidemiological studies are needed to uncover the functional, multidirectional associations between the specific microbiota strains, the host immune system and allergens.
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